Ziftomenib Gains Commercial Footing in R/R NPM1-Mutant AML, But Frontline Design and MRD Silence Carry Decisive Weight

Kura Oncology Reports Strong KOMZIFTI Sales and Positive Clinical Updates

Kura Oncology reported strong second-quarter 2026 financial results, highlighted by the successful commercial launch of KOMZIFTI (ziftomenib) for relapsed or refractory NPM1-mutant AML. Net product revenue reached $9.1 million, a 57% increase from Q1 2026, with new patient starts rising 35% to approximately 115, establishing KOMZIFTI as a leader in its class. The company also provided positive clinical updates for ziftomenib, including long-term data from the KOMET-007 trial in frontline AML showing high CRc and OS rates, and for darlifarnib, demonstrating promising activity in various solid tumors. Kura Oncology maintains a strong financial position with $519.0 million in cash and anticipated collaboration payments.

• KOMZIFTI (ziftomenib) achieved significant commercial momentum in its second full quarter post-launch, generating $9.1 million in net product revenue, a 57% increase over Q1 2026. With approximately 115 new patient starts, up 35% from Q1, KOMZIFTI secured a majority share of new patient starts in the R/R NPM1-m AML menin inhibitor class, indicating strong physician preference and establishing early market leadership.
• Long-term data from the KOMET-007 trial, presented at EHA 2026, highlighted ziftomenib's high and durable clinical activity. In newly diagnosed NPM1-m AML patients, ziftomenib plus intensive chemotherapy achieved a 96% composite complete remission (CRc) rate and a 94% 12-month overall survival (OS) rate. Updated KOMET-007 results in R/R NPM1-m AML showed an 87% overall response rate (ORR) and 70% CRc rate in venetoclax-naïve patients, supporting its potential as a foundational therapy.
• Darlifarnib demonstrated encouraging clinical activity as a precision combination platform in solid tumors. Phase 1 FIT-001 data showed tumor shrinkage in 77% of KRAS G12C-mutated solid tumor patients, with confirmed ORRs of 67% in pancreatic cancer and 50% in non-small cell lung cancer. In cabozantinib-exposed clear cell renal cell carcinoma, darlifarnib plus cabozantinib achieved a 44% ORR and 94% disease control rate, suggesting its ability to overcome resistance to VEGFR-targeted therapies.

Ziftomenib's Efficacy and Safety Across AML Treatment Settings

The KOMET-001 Phase II study evaluated ziftomenib, an oral menin inhibitor administered at 600 mg once daily, in 92 patients with relapsed or refractory NPM1-mutated AML (enrolled January 2023 to May 2024; median age 69 years, range 33–84). The study met its primary endpoint, demonstrating a CR/CRh rate of 22% (95% CI, 14–32; P = .0058), with 61% of responders achieving measurable residual disease negativity. The overall response rate was 33% (95% CI, 23–43), with a median duration of response of 4.6 months (95% CI, 2.8–7.4) and a median overall survival of 6.6 months (95% CI, 3.6–8.6). Notably, CR/CRh rates were comparable irrespective of prior venetoclax exposure or co-mutation profile, suggesting broad applicability within the NPM1-mutated population.

From a safety standpoint, ziftomenib demonstrated a generally manageable tolerability profile. The most common grade ≥3 treatment-emergent adverse events were febrile neutropenia (26%), anemia (20%), and thrombocytopenia (20%). Differentiation syndrome, a class effect associated with menin inhibitors, occurred in 25% of patients (15% grade 3; no grade 4–5 events) and was controlled with protocol-defined mitigation strategies. Clinically significant QTc prolongation was absent, and only 3 patients (3%) discontinued treatment due to ziftomenib-related adverse events, underscoring the drug's tolerability in a heavily pretreated population.

The AUGMENT-101 study investigated revumenib, another menin inhibitor, in a similarly pretreated relapsed/refractory AML population (n = 84 dosed; efficacy-evaluable n = 64; median age 63 years; 75.0% with prior venetoclax exposure). Revumenib achieved a CR+CRh rate of 23.4% (one-sided P = .0014) and an overall response rate of 46.9%, with a median CR+CRh duration of 4.7 months. Sixteen point seven percent of responders (5 of 30) proceeded to hematopoietic stem cell transplantation, with 3 subsequently resuming revumenib post-HSCT. Treatment-related adverse events led to discontinuation in only 4 patients (4.8%), and the overall safety profile was consistent with previously reported findings for this agent.

Addressing Unmet Needs in Relapsed/Refractory NPM1-m AML

Relapsed or refractory (R/R) NPM1-mutated AML remains an area of critical unmet need, characterized by poor outcomes despite initial response to intensive chemotherapy. Median overall survival in the relapsed setting is approximately 6.1 months (12-month OS: 30%; median relapse-free survival: 5.5 months), underscoring the urgency for effective therapeutic strategies. Recent clinical and translational efforts have converged on several distinct high-risk populations driving drug development in this space.

• Heavily pretreated, older patients: Clinical trials have specifically enrolled populations with significant prior treatment burden. The KOMET-001 phase II study (ziftomenib) enrolled 92 patients with a median age of 69 years (range 33–84), while the AUGMENT-101 study included 64 efficacy-evaluable adults, of whom 35.9% had received ≥3 prior lines of therapy and 75.0% had prior venetoclax exposure — a population with markedly limited salvage options.

• Patients harboring high-risk co-mutations: Those with concurrent FLT3-ITD and DNMT3A mutations represent a particularly poor-prognosis subgroup, demonstrating the lowest event-free and overall survival rates (3-year EFS: 30.0%; 3-year OS: 34.4%). Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been identified as a key intervention in this population, significantly improving outcomes versus chemotherapy alone (3-year EFS: 57.9% vs. 30.0%; 3-year OS: 72.9% vs. 34.4%).

• Patients with inadequate MRD clearance: Failure to achieve ≥3 log reduction in measurable residual disease following treatment (MRD2 < 3 log reduction) has been established as an independent predictor of inferior survival outcomes (EFS HR = 0.2; OS HR = 0.1 in multivariable analysis), identifying a subgroup in need of intensified or novel consolidation strategies.

• Post-allo-HSCT relapse: Relapse following allogeneic transplantation constitutes a distinct and largely refractory clinical scenario, where conventional salvage chemotherapy offers minimal survival benefit — representing one of the most pressing gaps in the current R/R NPM1-mutated AML treatment landscape.

Understanding Ziftomenib's Safety and Tolerability Profile

Ziftomenib has demonstrated a manageable safety profile across clinical studies in acute myeloid leukemia (AML) patients harboring KMT2A rearrangements and NPM1 mutations. Regulatory recognition of its benefit-risk profile is reflected in both orphan drug and breakthrough therapy designations granted by the EMA (January 2024) and FDA (April 2024) for relapsed/refractory NPM1-mutated AML.

• Differentiation syndrome occurs in 10–20% of patients treated with ziftomenib, representing an on-target effect of blast differentiation; this rate is consistent with other agents in the menin inhibitor class and underscores the need for proactive monitoring and management protocols.

• QT prolongation has been identified as a key cardiac toxicity associated with ziftomenib, necessitating routine cardiac monitoring throughout the course of therapy.

• Cytopenias represent an additional notable toxicity contributing to treatment-related morbidity in this heavily pretreated patient population.

• Pharmacokinetic and tolerability data from healthy volunteers (Phase 1) confirmed no new safety signals, with a median time to maximum concentration of 3.5 hours, an elimination half-life of 61.5 hours supporting once-daily dosing, absolute bioavailability of 12.9%, and primary excretion as unchanged drug in feces (89.7% of total radioactivity recovery in feces; 0.5% in urine).

KOMZIFTI's Ascent: Reshaping AML Treatment Paradigms

The impressive commercial launch of KOMZIFTI (ziftomenib) for relapsed or refractory NPM1-mutant AML underscores a pivotal moment in the treatment of acute leukemias. This success is not merely a financial win for Kura Oncology but a testament to the growing impact of precision medicine in addressing high-risk patient populations. NPM1-mutant AML, affecting approximately 30% of AML patients, has historically presented a significant challenge, particularly in the relapsed/refractory setting where prognosis is poor.

Menin inhibitors like ziftomenib offer a targeted approach by disrupting the oncogenic MEIS1-HOXA axis, a common driver in both NPM1-mutant and KMT2A-rearranged leukemias. The rapid uptake of KOMZIFTI, evidenced by its strong revenue growth and increasing patient starts, highlights the significant unmet need it addresses and its perceived value by clinicians.

Beyond its current indication, the positive long-term data from the KOMET-007 trial in frontline AML is particularly compelling. High composite complete remission and overall survival rates suggest a strong potential for ziftomenib to move into earlier lines of therapy, which would dramatically expand its market and impact. This strategic expansion could redefine treatment paradigms for newly diagnosed patients.

However, the journey for menin inhibitors is not without its complexities. Key considerations include:

• Durability and Resistance: While effective, single-agent menin inhibitor treatment has shown limited durability, with resistance mechanisms like MEN1 mutations or transcriptional reprogramming emerging. This necessitates ongoing research into combination strategies.

• Safety Profile: On-target effects such as differentiation syndrome (occurring in 10-20% of patients) and other toxicities like QTc prolongation or cytopenias require careful monitoring and management.

• Competitive Landscape: The field of menin inhibitors is dynamic, with several agents in various stages of development or approval. Maintaining a competitive edge will depend on demonstrating sustained efficacy, favorable safety, and strategic development into new indications or combination regimens.

Preclinical studies, for instance, have shown synergistic antileukemic activity when ziftomenib is combined with XPO1 inhibitors like selinexor, suggesting avenues for deepening responses and preventing relapse. The ongoing investigation into combination approaches with venetoclax, hypomethylating agents, or intensive chemotherapy in both frontline and relapsed/refractory settings will be crucial in solidifying the role of menin inhibitors as a cornerstone of AML therapy. Kura's strong financial position provides the necessary runway to navigate these challenges and capitalize on future opportunities.